<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304031</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-0525</org_study_id>
    <secondary_id>CDR0000465183</secondary_id>
    <secondary_id>EORTC-26052</secondary_id>
    <secondary_id>EORTC-22053</secondary_id>
    <secondary_id>NCI-2009-00731</secondary_id>
    <nct_id>NCT00304031</nct_id>
  </id_info>
  <brief_title>Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma</brief_title>
  <official_title>Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
      chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Giving radiation therapy
      together with temozolomide may kill more tumor cells. It is not yet known which schedule of
      temozolomide when given together with radiation therapy is more effective in treating
      glioblastoma or gliosarcoma.

      PURPOSE: This randomized phase III trial is studying two different schedules of temozolomide
      to compare how well they work when given together with radiation therapy in treating patients
      with newly diagnosed glioblastoma or gliosarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine if dose-intensifying (increasing the &quot;dose-density&quot;) the adjuvant temozolomide
           component of the chemoradiation treatment enhances treatment efficacy as measured by
           overall survival of patients with newly diagnosed glioblastoma or gliosarcoma.

      Secondary

        -  Determine if dose-intensifying the adjuvant temozolomide component of the chemoradiation
           treatment enhances treatment efficacy as measured by progression-free survival.

        -  Determine in patients with unmethylated MGMT (O-6-methylguanine-DNA methyltransferase)
           if dose-intensifying the adjuvant temozolomide component of the chemoradiation treatment
           enhances treatment efficacy (overall and progression-free survival) compared with
           patients receiving conventional temozolomide dosing.

        -  Determine in patients with methylated MGMT if dose-intensifying the adjuvant
           temozolomide component of the chemoradiation treatment enhances treatment efficacy
           (overall and progression-free survival) compared with patients receiving conventional
           temozolomide dosing.

        -  Determine if there is an association between tumor MGMT gene methylation status and
           treatment response.

        -  Compare and record the toxicities of the conventional and dose-intense chemotherapy
           regimens.

        -  Evaluate whether 6-month progression-free survival is associated with overall survival.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      recursive partitioning analysis class (III vs IV vs V), MGMT gene methylation status
      (methylated vs nonmethylated vs indeterminate), and radiotherapy criteria used (standard vs
      revised European).

      After completion of study treatment, patients are followed every 3 months for 1 year, every 4
      months for 2 years, and then every 6 months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Overall Survival Time</measure>
    <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
    <description>Overall survival time is defined as time from registration/randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Analysis occurred after 647 deaths were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival (PFS) Time</measure>
    <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
    <description>Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Analysis occurred after 647 deaths were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival Time by MGMT Status</measure>
    <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
    <description>Overall survival time is defined as time from randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival Time by MGMT Status</measure>
    <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
    <description>Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Treatment Response by MGMT Status</measure>
    <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
    <description>Response assessed using Response Evaluation Criteria in Solid Tumors (RECIST v1.0): Complete Response (CR), imaging no longer shows enhancing tumor, confirmed by a second scan â‰¥ 4 weeks later; Partial Response (PR), &gt;=50% decrease in tumor area (two diameters) with patient off all steroids, or on adrenal maintenance only; Minor Response (MR), &lt; 50% decrease in tumor area with patient off all steroids, or on adrenal maintenance only; Stable Disease (SD): scan shows no change with patient receiving stable/decreasing doses of steroids; Progression (P): &gt; 25% increase in tumor area with no decrease in steroid dose since last evaluation. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Highest Grade AE Reported as Possibly/Probably/Definitely Related to Protocol Treatment</measure>
    <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
    <description>Highest grade adverse event (AE) per subject was counted. Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. Analysis occurred after 647 deaths were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Status by Progression Status at 6 Months</measure>
    <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
    <description>Overall survival time is defined as time from registration to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy</measure>
    <time_frame>Baseline and cycle 10 (approximately 46 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Neurocognitive Function (NCF) Composite Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy</measure>
    <time_frame>Baseline and cycle 10 (approximately 46 weeks)</time_frame>
    <description>The NCF Composite score is the arithmetic mean of the Hopkins Verbal Learning Test - Revised (HVLT-R) (Free Recall, Delayed Recall, Delayed Recognition), Trail Making Test Part A (TMTA), Trail Making Test Part B (TMTB), and Controlled Oral Word Association (COWA) test scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean EORTC QLQ-C30 Global Health Status Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy</measure>
    <time_frame>Baseline and cycle 10 (approximately 46 weeks)</time_frame>
    <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Mid-cyle for Cycle 1</measure>
    <time_frame>Baseline and mid-cycle 1 (approximately 12 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Mid-cyle for Cycle 4</measure>
    <time_frame>Baseline and mid-cycle 4 (approximately 24 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EORTC QLQ-C30 Global Health Status Score at Mid-cyle for Cycle 1</measure>
    <time_frame>Baseline and mid-cycle 1 (approximately 12 weeks)</time_frame>
    <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EORTC QLQ-C30 Global Health Status Score at Mid-cyle for Cycle 4</measure>
    <time_frame>Baseline and mid-cycle 4 (approximately 24 weeks)</time_frame>
    <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean EORTC QLQ-C30 Global Health Status</measure>
    <time_frame>Baseline, 10,12, 22, 24, and 46 weeks</time_frame>
    <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline was calculated as time point value - baseline value with a positive change value indicating improved QOL from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Cycle 4</measure>
    <time_frame>baseline and cycle 4 (approximately 22 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Interference Score at Cycle 4</measure>
    <time_frame>baseline and cycle 4 (approximately 22 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (did not interfere) to 10 (interfered completely). The symptom interference score is the average of the symptom interference items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 1</measure>
    <time_frame>baseline and cycle 1 (approximately 10 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 (very poor) to 7 (excellent) such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). A score worse than baseline by at least 10 is considered deterioration.
The 2x2 frequency table of SS deterioration vs. GHS deterioration is presented as four rows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 4</measure>
    <time_frame>baseline and cycle 4 (approximately 22 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 (very poor) to 7 (excellent) such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). A score worse than baseline by at least 10 is considered deterioration.
The 2x2 frequency table of SS deterioration vs. GHS deterioration is presented as four rows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 10</measure>
    <time_frame>baseline and cycle 10 (approximately 46 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 (very poor) to 7 (excellent) such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). A score worse than baseline by at least 10 is considered deterioration.
The 2x2 frequency table of SS deterioration vs. GHS deterioration is presented as four rows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score Over Time</measure>
    <time_frame>Baseline, 10, 12, 22, 24, and 46 weeks</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Impactful Baseline Instruments on Overall Survival</measure>
    <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
    <description>Overall survival time is defined as time from registration/randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30 subscales are calculated as the mean of component items, then standardized such that subscale scores range from 0 to 100. A high score for a functional scale represents a healthy level of functioning. Controlled Oral Word Association (COWA) score is the sum of correct responses with a range of 0 to infinity. A higher score indicates better functioning. Hopkins Verbal Learning Test - Revised (HVLT-R) score ranges from 0 to 36 for total recall is 0 to 36, 0 to 12 for delayed recall, and -12 to 12 for recognition. A higher score indicates better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Neurocognitive Function (NCF) Composite Score Over Time</measure>
    <time_frame>Baseline, 10, 22, and 46 weeks</time_frame>
    <description>The NCF Composite score is the arithmetic mean of the HVLT-R (Free Recall, Delayed Recall, Delayed Recognition), TMTA, TMTB, and COWA scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition Score at Cycle 1</measure>
    <time_frame>baseline and cycle 1 (approximately 10 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
The HVLT-R Delayed Recognition raw score is the number of of correctly identified words minus the number of incorrectly identified words from a list of words including 12 nouns memorized 20 minutes prior. The raw score ranges from -12 to 12. with a higher score indicates better functioning. Scores are standardized (mean 0, standard deviation 1), adjusting for age,education, and gender as necessary. A score worse than baseline by at least two is considered deterioration.
The 2x2 frequency table of SS deterioration vs. HVLT-R deterioration is presented as four rows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition (DR) Score at Cycle 4</measure>
    <time_frame>baseline and cycle 4 (approximately 22 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
The HVLT-R Delayed Recognition raw score is the number of of correctly identified words minus the number of incorrectly identified words from a list of words including 12 nouns memorized 20 minutes prior. The raw score ranges from -12 to 12. with a higher score indicates better functioning. Scores are standardized (mean 0, standard deviation 1), adjusting for age,education, and gender as necessary. A score worse than baseline by at least two is considered deterioration.
The 2x2 frequency table of SS deterioration vs. HVLT-R deterioration is presented as four rows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition (DR) Score at Cycle 10</measure>
    <time_frame>baseline and cycle 10 (approximately 46 weeks)</time_frame>
    <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
The HVLT-R Delayed Recognition raw score is the number of of correctly identified words minus the number of incorrectly identified words from a list of words including 12 nouns memorized 20 minutes prior. The raw score ranges from -12 to 12. with a higher score indicates better functioning. Scores are standardized (mean 0, standard deviation 1), adjusting for age,education, and gender as necessary. A score worse than baseline by at least two is considered deterioration.
The 2x2 frequency table of SS deterioration vs. HVLT-R deterioration is presented as four rows.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1173</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Conventional adjuvant TMZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-dense adjuvant TMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No adjuvant TMZ (not randomized )</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent temozolomide</intervention_name>
    <description>Daily oral temozolomide (75 mg/m2) up to 49 doses.</description>
    <arm_group_label>Conventional adjuvant TMZ</arm_group_label>
    <arm_group_label>Dose-dense adjuvant TMZ</arm_group_label>
    <arm_group_label>No adjuvant TMZ (not randomized )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent radiation therapy</intervention_name>
    <description>60 Gy in 2 Gy fractions</description>
    <arm_group_label>Conventional adjuvant TMZ</arm_group_label>
    <arm_group_label>Dose-dense adjuvant TMZ</arm_group_label>
    <arm_group_label>No adjuvant TMZ (not randomized )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle</intervention_name>
    <description>Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.</description>
    <arm_group_label>Conventional adjuvant TMZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle</intervention_name>
    <description>Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.</description>
    <arm_group_label>Dose-dense adjuvant TMZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histopathologically proven diagnosis of glioblastoma. Since gliosarcoma is a variant
             of glioblastoma, gliosarcoma is also an eligible diagnosis.

          2. Patients must have at least 1 block of tissue available for analysis of MGMT status;
             fresh frozen tumor tissue acquisition is encouraged.

          3. Diagnosis must be established by open biopsy or tumor resection. Patients who have
             only had a stereotactic biopsy are not eligible.

          4. The tumor must have a supratentorial component.

          5. Patients must have recovered from the effects of surgery, postoperative infection, and
             other complications before study registration.

          6. A diagnostic contrast-enhanced magnetic resonance imaging (MRI) or computerized
             tomography (CT) scan (if MRI is not available) of the brain must be performed
             preoperatively and postoperatively. The postoperative scan must be done within 28 days
             of registration and prior to the initiation of radiotherapy. Preoperative and
             postoperative scans must be the same type. If CT scans were performed perioperatively,
             a CT and an MRI should be performed before randomization.

             6.1. Patients unable to undergo MRI imaging because of non-compatible devices can be
             enrolled, provided pre- and post-operative contrast-enhanced CT scans are obtained and
             are of sufficient quality.

          7. Therapy must begin â‰¤ 5 weeks after the most recent brain tumor surgery.

          8. History/physical examination within 14 days prior to study registration.

          9. Neurologic examination within 14 days prior to study registration.

         10. Documentation of steroid doses within 14 days prior to study registration and stable
             or decreasing steroid dose within 5 days prior to registration.

         11. Karnofsky performance status of â‰¥ 60.

         12. Age â‰¥ 18 years.

         13. Complete blood count (CBC)/differential obtained within 14 days prior to study
             registration, with adequate bone marrow function as defined below: 13.1 Absolute
             neutrophil count (ANC) â‰¥ 1500 cells/mm3. 13.2 Platelets â‰¥ 100,000 cells/mm3. 13.3
             Hemoglobin â‰¥ 10 g/dl. (Note: The use of transfusion or other intervention to achieve
             Hgb â‰¥ 10 g/dl is acceptable.)

         14. Adequate renal function, as defined below:

             14.1 Blood urea nitrogen (BUN) â‰¤ 25 mg/dl within 14 days prior to study registration
             14.2 Creatinine â‰¤ 1.7 mg/dl within 14 days prior to study registration

         15. Adequate hepatic function, as defined below:

             15.1 Bilirubin â‰¤ 2.0 mg/dl within 14 days prior to study registration 15.2 Alanine
             aminotransferase (ALT) â‰¤ 3 x normal range within 14 days prior to study registration
             15.3 Aspartate aminotransferase (AST) â‰¤ 3 x normal range within 14 days prior to study
             registration

         16. Patients must sign a study-specific informed consent prior to study registration.

             If the patient's mental status precludes his/her giving informed consent, written
             informed consent may be given by the responsible family member.

         17. For females of child-bearing potential, negative serum pregnancy test within 72 hours
             prior to starting temozolomide.

         18. Women of childbearing potential and male participants must practice adequate

        Exclusion criteria:

          1. Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease
             free for â‰¥ 3 years. (For example, carcinoma in situ of the breast, oral cavity, and
             cervix are all permissible).

          2. Recurrent or multifocal malignant gliomas

          3. Metastases detected below the tentorium or beyond the cranial vault.

          4. Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note
             that prior chemotherapy for a different cancer is allowable. Prior use of Gliadel
             wafers or any other intratumoral or intracavitary treatment are not permitted. See
             Section 1.

          5. Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in
             overlap of radiation fields.

          6. Severe, active co-morbidity, defined as follows:

               -  6.1. Unstable angina and/or congestive heart failure requiring hospitalization.

               -  6.2. Transmural myocardial infarction within the last 6 months.

               -  6.3. Acute bacterial or fungal infection requiring intravenous antibiotics at the
                  time of registration.

               -  6.4. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory
                  illness requiring hospitalization or precluding study therapy at the time of
                  registration.

               -  6.5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation
                  defects; note, however, that laboratory tests for liver function and coagulation
                  parameters are not required for entry into this protocol.

               -  6.6. Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for
                  Disease Control and Prevention (CDC) definition; note, however, that HIV testing
                  is not required for entry into this protocol. The need to exclude patients with
                  AIDS from this protocol is necessary because the treatments involved in this
                  protocol may be significantly immunosuppressive.

               -  6.7. Major medical illnesses or psychiatric impairments that in the
                  investigator's opinion will prevent administration or completion of protocol
                  therapy.

               -  6.8. Active connective tissue disorders, such as lupus or scleroderma, that in
                  the opinion of the treating physician may put the patient at high risk for
                  radiation toxicity.

          7. Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception; this exclusion is
             necessary because the treatment involved in this study may be significantly
             teratogenic.

          8. Pregnant or lactating women, due to possible adverse effects on the developing fetus
             or infant due to study drug;

          9. Prior allergic reaction to temozolomide.

         10. Patients treated on any other therapeutic clinical protocols within 30 days prior to
             study entry or during participation in the study.

         11. No tissue provided for histopathologic central review and MGMT status.

         12. Tissue provided by stereotactic biopsy method.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark R. Gilbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minesh P. Mehta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Stupp, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital</name>
      <address>
        <city>Fairbanks</city>
        <state>Alaska</state>
        <zip>99701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Services Foundation</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auburn Radiation Oncology</name>
      <address>
        <city>Auburn</city>
        <state>California</state>
        <zip>95603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Saint Joseph Medical Center - Burbank</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Centers - Cameron Park</name>
      <address>
        <city>Cameron Park</city>
        <state>California</state>
        <zip>95682</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center at Mercy San Juan Medical Center</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Center - Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiological Associates of Sacramento Medical Group, Incorporated</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solano Radiation Oncology Center</name>
      <address>
        <city>Vacaville</city>
        <state>California</state>
        <zip>95687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose Cancer Center at Penrose Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80933</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Radiation Oncology</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tunnell Cancer Center at Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network at Southside Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center South</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist-South Miami Regional Cancer Program</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network - Orange Park</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Center - Palatka</name>
      <address>
        <city>Palatka</city>
        <state>Florida</state>
        <zip>32177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flagler Cancer Center</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute at University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John B. Amos Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Community Hospital</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush-Copley Cancer Care Center</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graham Hospital</name>
      <address>
        <city>Canton</city>
        <state>Illinois</state>
        <zip>61520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>Carthage</city>
        <state>Illinois</state>
        <zip>62321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H. Stroger, Jr. Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3785</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eureka Community Hospital</name>
      <address>
        <city>Eureka</city>
        <state>Illinois</state>
        <zip>61530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galesburg Clinic, PC</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galesburg Cottage Hospital</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InterCommunity Cancer Center of Western Illinois</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mason District Hospital</name>
      <address>
        <city>Havana</city>
        <state>Illinois</state>
        <zip>62644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopedale Medical Complex</name>
      <address>
        <city>Hopedale</city>
        <state>Illinois</state>
        <zip>61747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates, Limited - West</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McDonough District Hospital</name>
      <address>
        <city>Macomb</city>
        <state>Illinois</state>
        <zip>61455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BroMenn Regional Medical Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of Central Illinois, PC - Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Center at Pekin Hospital</name>
      <address>
        <city>Pekin</city>
        <state>Illinois</state>
        <zip>61554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Proctor Hospital</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Illinois Oncology Research Association</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of Central Illinois, PC - Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Medical Center of Illinois</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Valley Community Hospital</name>
      <address>
        <city>Peru</city>
        <state>Illinois</state>
        <zip>61354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perry Memorial Hospital</name>
      <address>
        <city>Princeton</city>
        <state>Illinois</state>
        <zip>61356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Margaret's Hospital</name>
      <address>
        <city>Spring Valley</city>
        <state>Illinois</state>
        <zip>61362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Cancer Center</name>
      <address>
        <city>Spring Valley</city>
        <state>Illinois</state>
        <zip>61362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center at Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart General Hospital</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Associates Southwest</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Regional Cancer Center at Parkview Health</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers - East</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Community Hospital</name>
      <address>
        <city>Kokomo</city>
        <state>Indiana</state>
        <zip>46904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Therapy at LaPorte Hospital and Health Services</name>
      <address>
        <city>La Porte</city>
        <state>Indiana</state>
        <zip>46350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Anthony Memorial Health Centers</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern Indiana CR Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Regional Medical Center</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bend Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic, PC</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Capitol Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Stoddard Cancer Center at Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates at John Stoddard Cancer Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates at Mercy Cancer Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center at Mercy Medical Center - Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Stoddard Cancer Center at Iowa Lutheran Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center at Mercy Medical Center - North Iowa</name>
      <address>
        <city>Mason City</city>
        <state>Iowa</state>
        <zip>50401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Chanute</name>
      <address>
        <city>Chanute</city>
        <state>Kansas</state>
        <zip>66720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Dodge City</name>
      <address>
        <city>Dodge City</city>
        <state>Kansas</state>
        <zip>67801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - El Dorado</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas-Independence</name>
      <address>
        <city>Independence</city>
        <state>Kansas</state>
        <zip>67301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Kingman</name>
      <address>
        <city>Kingman</city>
        <state>Kansas</state>
        <zip>67068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Medical Center</name>
      <address>
        <city>Liberal</city>
        <state>Kansas</state>
        <zip>67901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Newton</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menorah Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers - Southwest</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Parsons</name>
      <address>
        <city>Parsons</city>
        <state>Kansas</state>
        <zip>67357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Pratt</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Salina</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shawnee Mission Medical Center</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Wellington</name>
      <address>
        <city>Wellington</city>
        <state>Kansas</state>
        <zip>67152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Womens Health, PA - North Review</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Medical Arts Tower</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Cancer Center at Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Winfield</name>
      <address>
        <city>Winfield</city>
        <state>Kansas</state>
        <zip>67156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DeCesaris Cancer Institute at Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Agnes Hospital Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Cancer Program at Union Hospital</name>
      <address>
        <city>Elkton</city>
        <state>Maryland</state>
        <zip>21921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hickman Cancer Center at Bixby Medical Center</name>
      <address>
        <city>Adrian</city>
        <state>Michigan</state>
        <zip>49221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakwood Cancer Center at Oakwood Hospital and Medical Center</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48123-2500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology, Limited - Escanaba</name>
      <address>
        <city>Escanaba</city>
        <state>Michigan</state>
        <zip>49431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesys Hurley Cancer Institute</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Van Elslander Cancer Center at St. John Hospital and Medical Center</name>
      <address>
        <city>Grosse Pointe Woods</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dickinson County Healthcare System</name>
      <address>
        <city>Iron Mountain</city>
        <state>Michigan</state>
        <zip>49801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foote Memorial Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematology-Oncology Associates of Ohio and Michigan, PC</name>
      <address>
        <city>Lambertville</city>
        <state>Michigan</state>
        <zip>48144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparrow Regional Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912-1811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center of Monroe</name>
      <address>
        <city>Monroe</city>
        <state>Michigan</state>
        <zip>48162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Memorial Hospital - Monroe</name>
      <address>
        <city>Monroe</city>
        <state>Michigan</state>
        <zip>48162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Oakland</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341-2985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Regional Cancer Center at Mercy Hospital</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Royal Oak Campus</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Cancer Institute at Saint Mary's - Saginaw</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Cancer Care Center - St. Joseph</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute at Providence Hospital - Southfield Campus</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Macomb Hospital</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <state>Minnesota</state>
        <zip>56308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MeritCare Bemidji</name>
      <address>
        <city>Bemidji</city>
        <state>Minnesota</state>
        <zip>56601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fergus Falls</city>
        <state>Minnesota</state>
        <zip>56537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA - Maplewood</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute at Abbott - Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422-2900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Clinic - River Campus</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coborn Cancer Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Cancer Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ridgeview Medical Center</name>
      <address>
        <city>Waconia</city>
        <state>Minnesota</state>
        <zip>55387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA - Woodbury</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independence Regional Health Center</name>
      <address>
        <city>Independence</city>
        <state>Missouri</state>
        <zip>64050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Medical Center</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Truman Medical Center - Hospital Hill</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute at Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Kansas City Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parvin Radiation Oncology</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers - South</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberty Hospital</name>
      <address>
        <city>Liberty</city>
        <state>Missouri</state>
        <zip>64068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Regional Medical Center</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Health Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hulston Cancer Center at Cox Medical Center South</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Montana Cancer Consortium</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Centers of the Northern Rockies - Billings</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Rockies Radiation Oncology Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Healthcare Cancer Care Services</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic - Downtown</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James Healthcare Cancer Care</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Falls Clinic - Main Facility</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Montana Hospital</name>
      <address>
        <city>Havre</city>
        <state>Montana</state>
        <zip>59501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier Oncology, PLLC</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalispell Medical Oncology at KRMC</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalispell Regional Medical Center</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Medical Center</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guardian Oncology and Center for Wellness</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Specialists at Montana Cancer Center</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59807-7877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Center at St. Patrick Hospital and Health Sciences Center</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Cancer Center at Good Samaritan Hospital</name>
      <address>
        <city>Kearney</city>
        <state>Nebraska</state>
        <zip>68848-1990</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Resource Center - Lincoln</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Estabrook Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegant Health Cancer Center at Bergan Mercy Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth - Hitchcock Concord</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingsbury Center for Cancer Care at Cheshire Medical Center</name>
      <address>
        <city>Keene</city>
        <state>New Hampshire</state>
        <zip>03431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Barnabas Medical Center Cancer Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederick R. and Betty M. Smith Cancer Treatment Center</name>
      <address>
        <city>Sparta</city>
        <state>New Jersey</state>
        <zip>07871</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Cooper - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monter Cancer Center of the North Shore-LIJ Health System</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Don Monti Comprehensive Cancer Center at North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Oncology Associates</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipson Cancer and Blood Center at Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospitals - Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Memorial Hospital, Incorporated</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Radiation Oncology</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutherford Hospital</name>
      <address>
        <city>Rutherfordton</city>
        <state>North Carolina</state>
        <zip>28139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmed Radiation Oncology Services</name>
      <address>
        <city>Wilson</city>
        <state>North Carolina</state>
        <zip>27893</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - MeritCare Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MeritCare Broadway</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McDowell Cancer Center at Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Center for Cancer Care at Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44309-2090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Rutan Hospital</name>
      <address>
        <city>Bellefontaine</city>
        <state>Ohio</state>
        <zip>43311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wood County Oncology Center</name>
      <address>
        <city>Bowling Green</city>
        <state>Ohio</state>
        <zip>43402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Cancer Center at Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710-1799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adena Regional Medical Center</name>
      <address>
        <city>Chillicothe</city>
        <state>Ohio</state>
        <zip>45601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center at Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital Cancer Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grant Medical Center Cancer Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Carmel Health - West Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital at Ohio Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center</name>
      <address>
        <city>Independence</city>
        <state>Ohio</state>
        <zip>44131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfield Medical Center</name>
      <address>
        <city>Lancaster</city>
        <state>Ohio</state>
        <zip>43130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lima Memorial Hospital</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strecker Cancer Center at Marietta Memorial Hospital</name>
      <address>
        <city>Marietta</city>
        <state>Ohio</state>
        <zip>45750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Ohio Oncology Center</name>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <zip>43537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <zip>43537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Licking Memorial Cancer Care Program at Licking Memorial Hospital</name>
      <address>
        <city>Newark</city>
        <state>Ohio</state>
        <zip>43055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Mercy Hospital</name>
      <address>
        <city>Oregon</city>
        <state>Ohio</state>
        <zip>43616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic - Oregon</name>
      <address>
        <city>Oregon</city>
        <state>Ohio</state>
        <zip>43616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK Medical Oncology Unit at Churchill Hospital &amp; Weatherall Institute of Molecular Medicine - Oxford</name>
      <address>
        <city>Salem</city>
        <state>Ohio</state>
        <zip>44460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Care, Incorporated</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital of Springfield and Clark County</name>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flower Hospital Cancer Center</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital of Tiffin</name>
      <address>
        <city>Tiffin</city>
        <state>Ohio</state>
        <zip>44883</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Mercy Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Ohio Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Toledo Community Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic, Incorporated - Main Clinic</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fulton County Health Center</name>
      <address>
        <city>Wauseon</city>
        <state>Ohio</state>
        <zip>43567</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Carmel St. Ann's Cancer Center</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Center</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis - Good Samaritan Hospital</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natalie Warren Bryant Cancer Center at St. Francis Hospital</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Center - Eugene</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Mount Hood Medical Center</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Milwaukie Hospital</name>
      <address>
        <city>Milwaukie</city>
        <state>Oregon</state>
        <zip>97222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Hospital &amp; Comprehensive Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center at Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213-2967</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adventist Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbia River Oncology Program</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital and Health Center and Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salem Hospital Regional Cancer Care Services</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97309-5014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Meridian Park Hospital</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenfeld Cancer Center at Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute at Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Radiation Oncology Center</name>
      <address>
        <city>Dunmore</city>
        <state>Pennsylvania</state>
        <zip>18512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dale and Frances Hughes Cancer Center at Pocono Medical Center</name>
      <address>
        <city>East Stroudsburg</city>
        <state>Pennsylvania</state>
        <zip>18301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riddle Memorial Hospital Cancer Center</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upper Delaware Valley Cancer Center</name>
      <address>
        <city>Milford</city>
        <state>Pennsylvania</state>
        <zip>18337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intercommunity Cancer Center</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alle-Kiski Medical Center</name>
      <address>
        <city>Natrona Heights</city>
        <state>Pennsylvania</state>
        <zip>15065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Paoli Memorial Hospital</name>
      <address>
        <city>Paoli</city>
        <state>Pennsylvania</state>
        <zip>19301-1792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center at Thomas Jefferson University - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankford Hospital Cancer Center - Torresdale Campus</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Cancer Center at Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19612-6052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Oncology Center</name>
      <address>
        <city>Somerset</city>
        <state>Pennsylvania</state>
        <zip>15501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Main Line Health</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Cancer Center at Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AnMed Cancer Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gibbs Regional Cancer Center at Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical X-Ray Center, PC</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center at Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Center West</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37392</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Center at Methodist</name>
      <address>
        <city>Oak Ridge</city>
        <state>Tennessee</state>
        <zip>37830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA at Texas Cancer Center Dallas Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klabzuba Cancer Center at Harris Methodist Fort Worth Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410-1894</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA at Texas Cancer Center - Sherman</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA at Texas Oncology Cancer Center Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Fork Hospital</name>
      <address>
        <city>American Fork</city>
        <state>Utah</state>
        <zip>84003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandra L. Maxwell Cancer Center</name>
      <address>
        <city>Cedar City</city>
        <state>Utah</state>
        <zip>84720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jon and Karen Huntsman Cancer Center at Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Val and Ann Browning Cancer Center at McKay-Dee Hospital Center</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Regional Medical Center - Provo</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dixie Regional Medical Center - East Campus</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists at UCS Cancer Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute at University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center - North</name>
      <address>
        <city>Saint Johnsbury</city>
        <state>Vermont</state>
        <zip>05819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fredericksburg Oncology, Incorporated</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Cancer Institute at Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Cancer Center</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cascade Cancer Center at Evergreen Hospital Medical Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Virginia Mason Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer Center at University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Washington Medical Center Cancer Center</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Star Lodge Cancer Center at Yakima Valley Memorial Hospital</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theda Care Cancer Institute</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301-3526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology, Limited at St. Mary's Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital Medical Center - Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital Regional Cancer Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Center for Cancer and Blood</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Cancer Care Center at Bay Area Medical Center</name>
      <address>
        <city>Marinette</city>
        <state>Wisconsin</state>
        <zip>54143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Memorial Hospital Cancer Care Center</name>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <zip>53051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center at Oconomowoc Memorial Hospital</name>
      <address>
        <city>Oconomowoc</city>
        <state>Wisconsin</state>
        <zip>53066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology, Limited - Oconto Falls</name>
      <address>
        <city>Oconto Falls</city>
        <state>Wisconsin</state>
        <zip>54154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Door County Cancer Center at Door County Memorial Hospital</name>
      <address>
        <city>Sturgeon Bay</city>
        <state>Wisconsin</state>
        <zip>54235-1495</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology, Limited - Sturgeon Bay</name>
      <address>
        <city>Sturgeon Bay</city>
        <state>Wisconsin</state>
        <zip>54235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waukesha Memorial Hospital Regional Cancer Center</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Program at Thunder Bay Regional Health Sciences</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Cancer Centre at McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre at Pasqua Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Aldape KD, Wang M, Sulman EP, et al.: RTOG 0525: molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma. [Abstract] J Clin Oncol 29 (Suppl 15): A-LBA2000, 2011.</citation>
  </results_reference>
  <results_reference>
    <citation>Armstrong TS, Wefel JS, Wang M, et al.: Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525. [Abstract] J Clin Oncol 29 (Suppl 15): A-2016, 2011.</citation>
  </results_reference>
  <results_reference>
    <citation>Wang M, Dignam J, Won M, et al.: Variation over time and interdependence between disease progression and death among patients with glioblastoma (GBM) on RTOG 0525. [Abstract] J Clin Oncol 29 (Suppl 15): A-2017, 2011.</citation>
  </results_reference>
  <results_reference>
    <citation>Aldape KD, Jones G, Wang M, et al.: MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma. [Abstract] J Clin Oncol 27 (Suppl 15): A-2051, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013 Nov 10;31(32):4085-91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7.</citation>
    <PMID>24101040</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>March 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2014</results_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Sites were required to submit participant tumor tissue for central histologic review and MGMT (O-6-methylguanine-DNA methyltransferase) status determination in order for registered participants to continue on the study. Of 1173 participants initially registered, 1125 participants met these requirements and started protocol treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>No Adjuvant TMZ (Not Randomized)</title>
          <description>Concurrent radiation therapy (RT) with concurrent temozolomide (TMZ) (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.</description>
        </group>
        <group group_id="P2">
          <title>Conventional Adjuvant TMZ</title>
          <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.</description>
        </group>
        <group group_id="P3">
          <title>Dose-dense Adjuvant TMZ</title>
          <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Concomitant RT+TMZ (Pre-randomization)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1125">All participants registered to concomitant treatment; randomized after completing this treatment.</participants>
                <participants group_id="P2" count="0">Participants were not randomized to adjuvant TMZ until after completion of concomitant treatment.</participants>
                <participants group_id="P3" count="0">Participants were not randomized to adjuvant TMZ until after completion of concomitant treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible Pre-randomization Population</title>
              <participants_list>
                <participants group_id="P1" count="1125"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible Pre-randomization Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1120"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="833">These participants completed concomitant treatment and met requirements for randomization.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible due to insufficient tissue</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient refusal</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician preference</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other complicating disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, not otherwise specified</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Randomization to Adjuvant TMZ Arm</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="411"/>
                <participants group_id="P3" count="422"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible Population</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="411"/>
                <participants group_id="P3" count="420"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Unmethylated MGMT Population</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="254"/>
                <participants group_id="P3" count="262"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Methylated MGMT Population</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Quality of Life Population</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="411">Randomized participants contributing data to results are considered to have completed the study.</participants>
                <participants group_id="P3" count="420">Randomized participants contributing data to results are considered to have completed the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No follow-up collected</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible patients who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>No Adjuvant TMZ (Not Randomized )</title>
          <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.</description>
        </group>
        <group group_id="B2">
          <title>Conventional Adjuvant TMZ</title>
          <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Dose-dense Adjuvant TMZ</title>
          <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="292"/>
            <count group_id="B2" value="411"/>
            <count group_id="B3" value="422"/>
            <count group_id="B4" value="1125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" lower_limit="22" upper_limit="87"/>
                    <measurement group_id="B2" value="57" lower_limit="22" upper_limit="84"/>
                    <measurement group_id="B3" value="58" lower_limit="21" upper_limit="84"/>
                    <measurement group_id="B4" value="58" lower_limit="21" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="483"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="237"/>
                    <measurement group_id="B4" value="642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Overall Survival Time</title>
        <description>Overall survival time is defined as time from registration/randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Analysis occurred after 647 deaths were reported.</description>
        <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
        <population>Randomized eligible patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (TMZ) (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival Time</title>
          <description>Overall survival time is defined as time from registration/randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Analysis occurred after 647 deaths were reported.</description>
          <population>Randomized eligible patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="14.9" upper_limit="18.0"/>
                    <measurement group_id="O2" value="14.9" lower_limit="13.7" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study was looking for a 20% reduction in hazard rate: null hypothesis (conventional arm): Median survival time (MST) = 14.0 mo.; alternative hypothesis (dose-dense arm): MST= 17.5 mo. A one-sided log-rank test at a significance level of 0.025 would have 80% power to detect this difference with a sample size of 750 patients (647 deaths were required for the final analysis).</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.63</p_value>
            <p_value_desc>One-sided</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>Reference level = Conventional adjuvant TMZ</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival (PFS) Time</title>
        <description>Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Analysis occurred after 647 deaths were reported.</description>
        <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
        <population>Randomized eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival (PFS) Time</title>
          <description>Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Analysis occurred after 647 deaths were reported.</description>
          <population>Randomized eligible patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.7" upper_limit="6.1"/>
                    <measurement group_id="O2" value="6.7" lower_limit="6.2" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>Two-side significance level = 0.05</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Reference level = Conventional adjuvant TMZ</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival Time by MGMT Status</title>
        <description>Overall survival time is defined as time from randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.</description>
        <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
        <population>MGMT status was not available for all randomized eligible participants. Therefore, data was only available from 376/411 on the conventional arm and 384/420 on the dose-dense arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival Time by MGMT Status</title>
          <description>Overall survival time is defined as time from randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.</description>
          <population>MGMT status was not available for all randomized eligible participants. Therefore, data was only available from 376/411 on the conventional arm and 384/420 on the dose-dense arm.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unmethylated MGMT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="13.2" upper_limit="16.5"/>
                    <measurement group_id="O2" value="13.3" lower_limit="12.3" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methylated MGMT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="17.6" upper_limit="29.0"/>
                    <measurement group_id="O2" value="20.2" lower_limit="15.4" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unmethylated MGMT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.44</p_value>
            <p_value_desc>One-sided significance level = 0.05</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>Reference level = Conventional adjuvant TMZ</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Methylated MGMT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>One-sided significance level = 0.05</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
            <estimate_desc>Reference level = Conventional adjuvant TMZ</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival Time by MGMT Status</title>
        <description>Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.</description>
        <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
        <population>MGMT status was not available for all randomized eligible participants. Therefore, data was only available from 376/411 on the conventional arm and 384/420 on the dose-dense arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival Time by MGMT Status</title>
          <description>Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.</description>
          <population>MGMT status was not available for all randomized eligible participants. Therefore, data was only available from 376/411 on the conventional arm and 384/420 on the dose-dense arm.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unmethylated MGMT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.3" upper_limit="5.7"/>
                    <measurement group_id="O2" value="6.0" lower_limit="5.5" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methylated MGMT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.1" upper_limit="9.6"/>
                    <measurement group_id="O2" value="10.1" lower_limit="7.9" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Unmethylated MGMT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>One-sided significance level = 0.05</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Reference level = Conventional adjuvant TMZ</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Methylated MGMT</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.33</p_value>
            <p_value_desc>One-sided significance level = 0.05</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Reference level = Conventional adjuvant TMZ</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Treatment Response by MGMT Status</title>
        <description>Response assessed using Response Evaluation Criteria in Solid Tumors (RECIST v1.0): Complete Response (CR), imaging no longer shows enhancing tumor, confirmed by a second scan â‰¥ 4 weeks later; Partial Response (PR), &gt;=50% decrease in tumor area (two diameters) with patient off all steroids, or on adrenal maintenance only; Minor Response (MR), &lt; 50% decrease in tumor area with patient off all steroids, or on adrenal maintenance only; Stable Disease (SD): scan shows no change with patient receiving stable/decreasing doses of steroids; Progression (P): &gt; 25% increase in tumor area with no decrease in steroid dose since last evaluation. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.</description>
        <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
        <population>Per the protocol, both arms are combined to compare between MGMT status. MGMT status and treatment response was not available for all randomized eligible participants. Therefore, data was only available for 748/831 randomized eligible patients (arms combined).</population>
        <group_list>
          <group group_id="O1">
            <title>Methylated</title>
            <description>Methylated MGMT (O[6]-methylguanine-DNA methyltransferase)</description>
          </group>
          <group group_id="O2">
            <title>Unmethylated</title>
            <description>Unmethylated MGMT (O[6]-methylguanine-DNA methyltransferase)</description>
          </group>
        </group_list>
        <measure>
          <title>Best Treatment Response by MGMT Status</title>
          <description>Response assessed using Response Evaluation Criteria in Solid Tumors (RECIST v1.0): Complete Response (CR), imaging no longer shows enhancing tumor, confirmed by a second scan â‰¥ 4 weeks later; Partial Response (PR), &gt;=50% decrease in tumor area (two diameters) with patient off all steroids, or on adrenal maintenance only; Minor Response (MR), &lt; 50% decrease in tumor area with patient off all steroids, or on adrenal maintenance only; Stable Disease (SD): scan shows no change with patient receiving stable/decreasing doses of steroids; Progression (P): &gt; 25% increase in tumor area with no decrease in steroid dose since last evaluation. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.</description>
          <population>Per the protocol, both arms are combined to compare between MGMT status. MGMT status and treatment response was not available for all randomized eligible participants. Therefore, data was only available for 748/831 randomized eligible patients (arms combined).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minor Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>Two-sided significance level of 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Highest Grade AE Reported as Possibly/Probably/Definitely Related to Protocol Treatment</title>
        <description>Highest grade adverse event (AE) per subject was counted. Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. Analysis occurred after 647 deaths were reported.</description>
        <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
        <population>Randomized eligible patients with any adverse events reported as possibly/probably/definitely related to protocol treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Highest Grade AE Reported as Possibly/Probably/Definitely Related to Protocol Treatment</title>
          <description>Highest grade adverse event (AE) per subject was counted. Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. Analysis occurred after 647 deaths were reported.</description>
          <population>Randomized eligible patients with any adverse events reported as possibly/probably/definitely related to protocol treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0,1,2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3,4,5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <method_desc>Two-sided significance level of 0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Status by Progression Status at 6 Months</title>
        <description>Overall survival time is defined as time from registration to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period.</description>
        <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
        <population>Per the protocol, both arms are combined to compare between 6-month progression status. Eligible pre-randomization participants with any follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>No Progression at 6 Months</title>
          </group>
          <group group_id="O2">
            <title>Progression at 6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Status by Progression Status at 6 Months</title>
          <description>Overall survival time is defined as time from registration to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period.</description>
          <population>Per the protocol, both arms are combined to compare between 6-month progression status. Eligible pre-randomization participants with any follow-up data.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="676"/>
                <count group_id="O2" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" lower_limit="19.5" upper_limit="22.2"/>
                    <measurement group_id="O2" value="10.1" lower_limit="8.8" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two-sided test</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed.</description>
        <time_frame>Baseline and cycle 10 (approximately 46 weeks)</time_frame>
        <population>Cycle 10 questionnaires were not completed by all quality of life (QOL) population participants progression-free at 6 months. Therefore, only 24/96 on the conventional arm and 20/95 on the dose-dense arm had data.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed.</description>
          <population>Cycle 10 questionnaires were not completed by all quality of life (QOL) population participants progression-free at 6 months. Therefore, only 24/96 on the conventional arm and 20/95 on the dose-dense arm had data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="0.72" upper_limit="1.61"/>
                    <measurement group_id="O2" value="1.18" lower_limit="0.68" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Neurocognitive Function (NCF) Composite Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy</title>
        <description>The NCF Composite score is the arithmetic mean of the Hopkins Verbal Learning Test - Revised (HVLT-R) (Free Recall, Delayed Recall, Delayed Recognition), Trail Making Test Part A (TMTA), Trail Making Test Part B (TMTB), and Controlled Oral Word Association (COWA) test scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function.</description>
        <time_frame>Baseline and cycle 10 (approximately 46 weeks)</time_frame>
        <population>Cycle 10 questionnaires were not completed by all QOL population participants progression-free at 6 months. Therefore, only 17/96 on the conventional arm and 20/95 on the dose-dense arm had data.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Neurocognitive Function (NCF) Composite Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy</title>
          <description>The NCF Composite score is the arithmetic mean of the Hopkins Verbal Learning Test - Revised (HVLT-R) (Free Recall, Delayed Recall, Delayed Recognition), Trail Making Test Part A (TMTA), Trail Making Test Part B (TMTB), and Controlled Oral Word Association (COWA) test scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function.</description>
          <population>Cycle 10 questionnaires were not completed by all QOL population participants progression-free at 6 months. Therefore, only 17/96 on the conventional arm and 20/95 on the dose-dense arm had data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" lower_limit="-2.12" upper_limit="0.21"/>
                    <measurement group_id="O2" value="-1.19" lower_limit="-2.03" upper_limit="-0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean EORTC QLQ-C30 Global Health Status Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy</title>
        <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best).</description>
        <time_frame>Baseline and cycle 10 (approximately 46 weeks)</time_frame>
        <population>Cycle 10 questionnaires were not completed by all QOL population participants progression-free at 6 months. Therefore, only 24/96 on the conventional arm and 22/95 on the dose-dense arm had data.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean EORTC QLQ-C30 Global Health Status Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy</title>
          <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best).</description>
          <population>Cycle 10 questionnaires were not completed by all QOL population participants progression-free at 6 months. Therefore, only 24/96 on the conventional arm and 22/95 on the dose-dense arm had data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" lower_limit="64.6" upper_limit="81.9"/>
                    <measurement group_id="O2" value="69.7" lower_limit="60.1" upper_limit="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Mid-cyle for Cycle 1</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
        <time_frame>Baseline and mid-cycle 1 (approximately 12 weeks)</time_frame>
        <population>Questionnaires were not completed by all QOL population participants. Therefore, only 41/96 on the conventional arm and 35/95 on the dose-dense arm have both baseline and mid-cycle 1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Mid-cyle for Cycle 1</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
          <population>Questionnaires were not completed by all QOL population participants. Therefore, only 41/96 on the conventional arm and 35/95 on the dose-dense arm have both baseline and mid-cycle 1 data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.06" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.39" lower_limit="-0.08" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Mid-cyle for Cycle 4</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
        <time_frame>Baseline and mid-cycle 4 (approximately 24 weeks)</time_frame>
        <population>Questionnaires were not completed by all QOL population participants. Therefore, only 32/96 on the conventional arm and 24/95 on the dose-dense arm have both baseline and mid-cycle 4 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Mid-cyle for Cycle 4</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
          <population>Questionnaires were not completed by all QOL population participants. Therefore, only 32/96 on the conventional arm and 24/95 on the dose-dense arm have both baseline and mid-cycle 4 data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" lower_limit="-0.69" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.19" lower_limit="-0.40" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EORTC QLQ-C30 Global Health Status Score at Mid-cyle for Cycle 1</title>
        <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
        <time_frame>Baseline and mid-cycle 1 (approximately 12 weeks)</time_frame>
        <population>Questionnaires were not completed by all QOL population participants. Therefore, only 40/96 on the conventional arm and 38/95 on the dose-dense arm have both baseline and mid-cycle 1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EORTC QLQ-C30 Global Health Status Score at Mid-cyle for Cycle 1</title>
          <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
          <population>Questionnaires were not completed by all QOL population participants. Therefore, only 40/96 on the conventional arm and 38/95 on the dose-dense arm have both baseline and mid-cycle 1 data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.58" lower_limit="-12.63" upper_limit="3.47"/>
                    <measurement group_id="O2" value="-2.63" lower_limit="-11.37" upper_limit="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EORTC QLQ-C30 Global Health Status Score at Mid-cyle for Cycle 4</title>
        <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
        <time_frame>Baseline and mid-cycle 4 (approximately 24 weeks)</time_frame>
        <population>Questionnaires were not completed by all QOL population participants. Therefore, only 30/96 on the conventional arm and 23/95 on the dose-dense arm have both baseline and mid-cycle 4 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EORTC QLQ-C30 Global Health Status Score at Mid-cyle for Cycle 4</title>
          <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline.</description>
          <population>Questionnaires were not completed by all QOL population participants. Therefore, only 30/96 on the conventional arm and 23/95 on the dose-dense arm have both baseline and mid-cycle 4 data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.78" lower_limit="-13.87" upper_limit="8.32"/>
                    <measurement group_id="O2" value="-0.72" lower_limit="-11.91" upper_limit="10.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean EORTC QLQ-C30 Global Health Status</title>
        <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline was calculated as time point value - baseline value with a positive change value indicating improved QOL from baseline.</description>
        <time_frame>Baseline, 10,12, 22, 24, and 46 weeks</time_frame>
        <population>Questionnaires were not completed by all QOL population participants. Therefore, the number of participants reported below are the number with the relevant questions answered at baseline and the given time point on each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean EORTC QLQ-C30 Global Health Status</title>
          <description>Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 &quot;very poor&quot; to 7 &quot;excellent&quot; such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline was calculated as time point value - baseline value with a positive change value indicating improved QOL from baseline.</description>
          <population>Questionnaires were not completed by all QOL population participants. Therefore, the number of participants reported below are the number with the relevant questions answered at baseline and the given time point on each arm.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 10 (Cycle 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.1" upper_limit="6.1"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-8.7" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Cycle 1.5)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" lower_limit="-12.6" upper_limit="3.5"/>
                    <measurement group_id="O2" value="-2.7" lower_limit="-11.3" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22 (Cycle 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="-2.5" upper_limit="10.4"/>
                    <measurement group_id="O2" value="-4.4" lower_limit="-12.1" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Cycle 4.5)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" lower_limit="-13.9" upper_limit="8.3"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-11.9" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 46 (Cycle 10)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="-7.5" upper_limit="18.3"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-9.8" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model was run with EORTC QLQ-C30 Global Health Status Score (baseline, 10,12, 22, 24, and 46 weeks) as the outcome of interest. Treatment arm, recursive partitioning analysis (RPA) class, MGMT status, and time were included in the model. Treatment arm is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2184</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Each explanatory variable is reported separately. (Time and intercept effects are not shown.)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model was run with EORTC QLQ-C30 Global Health Status Score (baseline, 10,12, 22, 24, and 46 weeks) as the outcome of interest. Treatment arm, RPA class, MGMT status, and time were included in the model. RPA class is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0763</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Each explanatory variable is reported separately. (Time and intercept effects are not shown.)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model was run with EORTC QLQ-C30 Global Health Status Score (baseline, 10,12, 22, 24, and 46 weeks) as the outcome of interest. Treatment arm, RPA class, MGMT status, and time were included in the model. MGMT status is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5235</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Each explanatory variable is reported separately. (Time and intercept effects are not shown.)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Cycle 4</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.</description>
        <time_frame>baseline and cycle 4 (approximately 22 weeks)</time_frame>
        <population>Questionnaires were not completed by all QOL population participants. Therefore, only 51/96 on the conventional arm and 40/95 on the dose-dense arm have both baseline and cycle 4 data</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Cycle 4</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.</description>
          <population>Questionnaires were not completed by all QOL population participants. Therefore, only 51/96 on the conventional arm and 40/95 on the dose-dense arm have both baseline and cycle 4 data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Z-test of two proportions</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Interference Score at Cycle 4</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (did not interfere) to 10 (interfered completely). The symptom interference score is the average of the symptom interference items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.</description>
        <time_frame>baseline and cycle 4 (approximately 22 weeks)</time_frame>
        <population>Questionnaires were not completed by all QOL population participants. Therefore, only 51/96 on the conventional arm and 40/95 on the dose-dense arm have both baseline and cycle 4 data</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Interference Score at Cycle 4</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (did not interfere) to 10 (interfered completely). The symptom interference score is the average of the symptom interference items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.</description>
          <population>Questionnaires were not completed by all QOL population participants. Therefore, only 51/96 on the conventional arm and 40/95 on the dose-dense arm have both baseline and cycle 4 data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Z-test of two proportions</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 1</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 (very poor) to 7 (excellent) such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). A score worse than baseline by at least 10 is considered deterioration.
The 2x2 frequency table of SS deterioration vs. GHS deterioration is presented as four rows.</description>
        <time_frame>baseline and cycle 1 (approximately 10 weeks)</time_frame>
        <population>Per the protocol, both arms are combined. Questionnaires were not completed by all QOL population participants. Therefore, only 136/191 have both MDASI-BT and EORTC QLQ-C30 at baseline and cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Both Arms Combined</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, either [100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle] or [75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle] for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 1</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 (very poor) to 7 (excellent) such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). A score worse than baseline by at least 10 is considered deterioration.
The 2x2 frequency table of SS deterioration vs. GHS deterioration is presented as four rows.</description>
          <population>Per the protocol, both arms are combined. Questionnaires were not completed by all QOL population participants. Therefore, only 136/191 have both MDASI-BT and EORTC QLQ-C30 at baseline and cycle 1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Symptom Severity and GHS deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Symptom Severity deterioration only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>GHS deterioratoin only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Chi-squared</method>
            <method_desc>Two-sided test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 4</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 (very poor) to 7 (excellent) such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). A score worse than baseline by at least 10 is considered deterioration.
The 2x2 frequency table of SS deterioration vs. GHS deterioration is presented as four rows.</description>
        <time_frame>baseline and cycle 4 (approximately 22 weeks)</time_frame>
        <population>Both arms are combined per the protocol. Questionnaires were not completed by all QOL population participants. Therefore, only 86/191 have both MDASI-BT and EORTC QLQ-C30 at baseline and cycle 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Both Arms Combined</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, either [100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle] or [75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle] for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 4</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 (very poor) to 7 (excellent) such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). A score worse than baseline by at least 10 is considered deterioration.
The 2x2 frequency table of SS deterioration vs. GHS deterioration is presented as four rows.</description>
          <population>Both arms are combined per the protocol. Questionnaires were not completed by all QOL population participants. Therefore, only 86/191 have both MDASI-BT and EORTC QLQ-C30 at baseline and cycle 4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Symptom Severity and GHS deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Symptom Severity deterioration only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>GHS deterioration Only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Fisher Exact</method>
            <method_desc>Two-sided test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 10</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 (very poor) to 7 (excellent) such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). A score worse than baseline by at least 10 is considered deterioration.
The 2x2 frequency table of SS deterioration vs. GHS deterioration is presented as four rows.</description>
        <time_frame>baseline and cycle 10 (approximately 46 weeks)</time_frame>
        <population>Both arms are combined per the protocol. Questionnaires were not completed by all QOL population participants. Therefore, only 44/191 have both MDASI-BT and EORTC QLQ-C30 at baseline and cycle 10.</population>
        <group_list>
          <group group_id="O1">
            <title>Both Arms Combined</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, either [100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle] or [75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle] for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 10</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 (very poor) to 7 (excellent) such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). A score worse than baseline by at least 10 is considered deterioration.
The 2x2 frequency table of SS deterioration vs. GHS deterioration is presented as four rows.</description>
          <population>Both arms are combined per the protocol. Questionnaires were not completed by all QOL population participants. Therefore, only 44/191 have both MDASI-BT and EORTC QLQ-C30 at baseline and cycle 10.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Symptom Severity and GHS deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Symptom Severity deterioration only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>GHS deterioration only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Fisher Exact</method>
            <method_desc>Two-sided test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score Over Time</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed.</description>
        <time_frame>Baseline, 10, 12, 22, 24, and 46 weeks</time_frame>
        <population>Questionnaires were not completed by all QOL population participants. Therefore, the number of participants reported below are the number with the relevant questions answered at baseline and the given time point on each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score Over Time</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed.</description>
          <population>Questionnaires were not completed by all QOL population participants. Therefore, the number of participants reported below are the number with the relevant questions answered at baseline and the given time point on each arm.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.8" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (Cycle 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.1" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.1" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Cycle 1.5)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.2" upper_limit="2.1"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.1" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22 (Cycle 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.7" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.9" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Cycle 4.5)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.7" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.7" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 46 (Cycle 10)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.7" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.7" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model was run with MDASI Symptom Severity Score (baseline, 10, 12, 22, 24, 46 weeks) as the outcome of interest. Treatment arm, recursive partitioning analysis (RPA) class, MGMT status, and time were included in the model. Treatment arm is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Each explanatory variable is reported separately. (Time and intercept effects are not shown.)</non_inferiority_desc>
            <p_value>0.1702</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model was run with EORTC QLQ-C30 Global Health Status Score (baseline, 10, 12, 22, 24, 46 weeks) as the outcome of interest. Treatment arm, recursive partitioning analysis (RPA) class, MGMT status, and time were included in the model. RPA is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8159</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Each explanatory variable is reported separately. (Time and intercept effects are not shown.)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model was run with EORTC QLQ-C30 Global Health Status Score (baseline, 10, 12, 22, 24, 46 weeks) as the outcome of interest. Treatment arm, recursive partitioning analysis (RPA) class, MGMT status, and time were included in the model. MGMT status is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2174</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Each explanatory variable is reported separately. (Time and intercept effects are not shown.)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of Impactful Baseline Instruments on Overall Survival</title>
        <description>Overall survival time is defined as time from registration/randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30 subscales are calculated as the mean of component items, then standardized such that subscale scores range from 0 to 100. A high score for a functional scale represents a healthy level of functioning. Controlled Oral Word Association (COWA) score is the sum of correct responses with a range of 0 to infinity. A higher score indicates better functioning. Hopkins Verbal Learning Test - Revised (HVLT-R) score ranges from 0 to 36 for total recall is 0 to 36, 0 to 12 for delayed recall, and -12 to 12 for recognition. A higher score indicates better functioning.</description>
        <time_frame>From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.</time_frame>
        <population>Both arms are combined per the protocol. Questionnaires/assessments were not completed by all QOL population participants. Therefore, only 154/191 have COWA, EORTC QLQ-C30, and HVLT-R baseline assessments (final model covariates)</population>
        <group_list>
          <group group_id="O1">
            <title>Both Arms Combined</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, either [100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle] or [75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle] for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of Impactful Baseline Instruments on Overall Survival</title>
          <description>Overall survival time is defined as time from registration/randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30 subscales are calculated as the mean of component items, then standardized such that subscale scores range from 0 to 100. A high score for a functional scale represents a healthy level of functioning. Controlled Oral Word Association (COWA) score is the sum of correct responses with a range of 0 to infinity. A higher score indicates better functioning. Hopkins Verbal Learning Test - Revised (HVLT-R) score ranges from 0 to 36 for total recall is 0 to 36, 0 to 12 for delayed recall, and -12 to 12 for recognition. A higher score indicates better functioning.</description>
          <population>Both arms are combined per the protocol. Questionnaires/assessments were not completed by all QOL population participants. Therefore, only 154/191 have COWA, EORTC QLQ-C30, and HVLT-R baseline assessments (final model covariates)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="14.0" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A Cox proportional hazards model was run with overall survival as the outcome of interest and baseline scores as continuous covariates. The final model was determined from stepwise selection. EORTC physical functioning, EORTC role functioning, standardized HVLT-R recognition, standardized HVLT-R recall, and standardized COWA were included in the initial model. EORTC physical functioning is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A Cox proportional hazards model was run with overall survival as the outcome of interest and baseline scores as continuous covariates. The final model was determined from stepwise selection. EORTC physical functioning, EORTC role functioning, standardized HVLT-R recognition, standardized HVLT-R recall, and standardized COWA were included in the initial model. Standardized HVLT-R recognition is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A Cox proportional hazards model was run with overall survival as the outcome of interest and baseline scores as continuous covariates. The final model was determined from stepwise selection. EORTC physical functioning, EORTC role functioning, standardized HVLT-R recognition, standardized HVLT-R recall, and standardized COWA were included in the initial model. Standardized COWA is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Regression, Cox</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Neurocognitive Function (NCF) Composite Score Over Time</title>
        <description>The NCF Composite score is the arithmetic mean of the HVLT-R (Free Recall, Delayed Recall, Delayed Recognition), TMTA, TMTB, and COWA scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function.</description>
        <time_frame>Baseline, 10, 22, and 46 weeks</time_frame>
        <population>Questionnaires were not completed by all QOL population participants. Therefore, the number of participants reported below are the number with data at baseline and the given time point on each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Adjuvant TMZ</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose-dense Adjuvant TMZ</title>
            <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Neurocognitive Function (NCF) Composite Score Over Time</title>
          <description>The NCF Composite score is the arithmetic mean of the HVLT-R (Free Recall, Delayed Recall, Delayed Recognition), TMTA, TMTB, and COWA scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function.</description>
          <population>Questionnaires were not completed by all QOL population participants. Therefore, the number of participants reported below are the number with data at baseline and the given time point on each arm.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-1.6" upper_limit="-0.9"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-1.8" upper_limit="-1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (Cycle 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-1.7" upper_limit="-1.0"/>
                    <measurement group_id="O2" value="-1.45" lower_limit="-1.9" upper_limit="-1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22 (Cycle 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-1.6" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-2.0" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 46 (Cycle 10)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-2.1" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-2.0" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model was run with NCF Composite Score (baseline, 10, 22, 46 weeks) as the outcome of interest. Treatment arm, recursive partitioning analysis (RPA) class, MGMT status, and time were included in the model. Treatment arm is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2357</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Each explanatory variable is reported separately. (Time and intercept effects are not shown.)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model was run with NCF Composite Score (baseline, 10, 22, 46 weeks) as the outcome of interest. Treatment arm, recursive partitioning analysis (RPA) class, MGMT status, and time were included in the model. RPA is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0147</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Each explanatory variable is reported separately. (Time and intercept effects are not shown.)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model was run with NCF Composite Score (baseline, 10, 22, 46 weeks) as the outcome of interest. Treatment arm, recursive partitioning analysis (RPA) class, MGMT status, and time were included in the model. MGMT Status is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.457</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Each explanatory variable is reported separately. (Time and intercept effects are not shown.)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition Score at Cycle 1</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
The HVLT-R Delayed Recognition raw score is the number of of correctly identified words minus the number of incorrectly identified words from a list of words including 12 nouns memorized 20 minutes prior. The raw score ranges from -12 to 12. with a higher score indicates better functioning. Scores are standardized (mean 0, standard deviation 1), adjusting for age,education, and gender as necessary. A score worse than baseline by at least two is considered deterioration.
The 2x2 frequency table of SS deterioration vs. HVLT-R deterioration is presented as four rows.</description>
        <time_frame>baseline and cycle 1 (approximately 10 weeks)</time_frame>
        <population>Both arms are combined per the protocol. Questionnaires/assessments were not completed by all QOL population participants. Therefore, only 116/191 have both MDASI-BT and HVLT-R at baseline and cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Both Arms Combined</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, either [100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle] or [75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle] for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition Score at Cycle 1</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
The HVLT-R Delayed Recognition raw score is the number of of correctly identified words minus the number of incorrectly identified words from a list of words including 12 nouns memorized 20 minutes prior. The raw score ranges from -12 to 12. with a higher score indicates better functioning. Scores are standardized (mean 0, standard deviation 1), adjusting for age,education, and gender as necessary. A score worse than baseline by at least two is considered deterioration.
The 2x2 frequency table of SS deterioration vs. HVLT-R deterioration is presented as four rows.</description>
          <population>Both arms are combined per the protocol. Questionnaires/assessments were not completed by all QOL population participants. Therefore, only 116/191 have both MDASI-BT and HVLT-R at baseline and cycle 1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cognitive and HVLT-R deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cognitive deterioration only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HVLT-R deterioration only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
            <method_desc>Two-sided test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition (DR) Score at Cycle 4</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
The HVLT-R Delayed Recognition raw score is the number of of correctly identified words minus the number of incorrectly identified words from a list of words including 12 nouns memorized 20 minutes prior. The raw score ranges from -12 to 12. with a higher score indicates better functioning. Scores are standardized (mean 0, standard deviation 1), adjusting for age,education, and gender as necessary. A score worse than baseline by at least two is considered deterioration.
The 2x2 frequency table of SS deterioration vs. HVLT-R deterioration is presented as four rows.</description>
        <time_frame>baseline and cycle 4 (approximately 22 weeks)</time_frame>
        <population>Both arms are combined per the protocol. Questionnaires/assessments were not completed by all QOL population participants. Therefore, only 71/191 have both MDASI-BT and HVLT-R at baseline and cycle 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Both Arms Combined</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, either [100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle] or [75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle] for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition (DR) Score at Cycle 4</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
The HVLT-R Delayed Recognition raw score is the number of of correctly identified words minus the number of incorrectly identified words from a list of words including 12 nouns memorized 20 minutes prior. The raw score ranges from -12 to 12. with a higher score indicates better functioning. Scores are standardized (mean 0, standard deviation 1), adjusting for age,education, and gender as necessary. A score worse than baseline by at least two is considered deterioration.
The 2x2 frequency table of SS deterioration vs. HVLT-R deterioration is presented as four rows.</description>
          <population>Both arms are combined per the protocol. Questionnaires/assessments were not completed by all QOL population participants. Therefore, only 71/191 have both MDASI-BT and HVLT-R at baseline and cycle 4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cognitive and Delayed Recognition deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cognitive deterioration only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Delayed Recognition deterioration only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Fisher Exact</method>
            <method_desc>Two-sided test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition (DR) Score at Cycle 10</title>
        <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
The HVLT-R Delayed Recognition raw score is the number of of correctly identified words minus the number of incorrectly identified words from a list of words including 12 nouns memorized 20 minutes prior. The raw score ranges from -12 to 12. with a higher score indicates better functioning. Scores are standardized (mean 0, standard deviation 1), adjusting for age,education, and gender as necessary. A score worse than baseline by at least two is considered deterioration.
The 2x2 frequency table of SS deterioration vs. HVLT-R deterioration is presented as four rows.</description>
        <time_frame>baseline and cycle 10 (approximately 46 weeks)</time_frame>
        <population>Both arms are combined per the protocol. Questionnaires/assessments were not completed by all QOL population participants. Therefore, only 36/191 have both MDASI-BT and HVLT-R at baseline and cycle 10.</population>
        <group_list>
          <group group_id="O1">
            <title>Both Arms Combined</title>
            <description>Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, either [100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle] or [75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle] for 6 cycles, up to 12 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition (DR) Score at Cycle 10</title>
          <description>The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity (SS) and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). A SS score is the average of the SS items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration.
The HVLT-R Delayed Recognition raw score is the number of of correctly identified words minus the number of incorrectly identified words from a list of words including 12 nouns memorized 20 minutes prior. The raw score ranges from -12 to 12. with a higher score indicates better functioning. Scores are standardized (mean 0, standard deviation 1), adjusting for age,education, and gender as necessary. A score worse than baseline by at least two is considered deterioration.
The 2x2 frequency table of SS deterioration vs. HVLT-R deterioration is presented as four rows.</description>
          <population>Both arms are combined per the protocol. Questionnaires/assessments were not completed by all QOL population participants. Therefore, only 36/191 have both MDASI-BT and HVLT-R at baseline and cycle 10.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cognitive and Delayed Recognition deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cognitive deterioration only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Delayed Recognition deterioration only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No deterioration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Fisher Exact</method>
            <method_desc>Two-sided test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Eligible participants with adverse event data: concurrent RT and TMZ only arm (not randomized): 285/292; conventional adjuvant TMZ arm: 409/411; dose-dense adjuvant TMZ arm: 420/422.</desc>
      <group_list>
        <group group_id="E1">
          <title>No Adjuvant TMZ (Not Randomized)</title>
          <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.</description>
        </group>
        <group group_id="E2">
          <title>Conventional Adjuvant TMZ</title>
          <description>Concurrent radiation therapy with concurrent temozolomide (TMZ) (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.</description>
        </group>
        <group group_id="E3">
          <title>Dose-dense Adjuvant TMZ</title>
          <description>Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="142" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/bone marrow - Other:</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bone marrow depression NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Haemolysis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other:</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Extraocular muscle disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Ocular/visual - Other:</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Colitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastritis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other:</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Oseophagitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pancreatitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Small intestinal stricture NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other:</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Edema: head and neck:</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Edema: limb:</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gait abnormal NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pain - Other:</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy/immunology - Other:</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypersensitivity NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Arthritis infective NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bladder infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bone infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Bronchitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Encephalitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Eye infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection - Other:</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Biliary tree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Bladder (urinary)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Meninges (meningitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Rectum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Soft tissue NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils: Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils: Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils: Nerve-peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils: Wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC: Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC: Meninges (meningitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC: Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Infectous meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Opportunisitic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sepsis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Sinusitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vascular access NOS complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Leukopenia NOS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Metabolic/laboratory - Other:</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Alkalosis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypoglycemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Muscle weakness NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy): Extremity-lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy): Extremity-upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy): Left-sided</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy): Right-sided</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue - Other:</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>CNS necrosis/cystic progression:</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Convulsions NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hydrocephalus acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyperreflexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy): Facial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Neuralgia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Neurology - Other:</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial: CN VIII Hearing and balance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Psychosis aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Renal failure NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions:</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pneumonitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pulmonary/upper respiratory - Other:</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Respiratory tract hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypotension NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="376" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="392" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/visual - Other:</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="228" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: head and neck:</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Edema: limb:</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="292" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="320" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pain - Other:</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis radiation NOS</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Radiation recall syndrome</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Leukopenia NOS</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="190" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="179" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Metabolic/laboratory - Other:</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="163" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypoglycemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Muscle weakness NOS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy): Extremity-lower</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy): Left-sided</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Convulsions NOS</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="199" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Hyperreflexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Neurology - Other:</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative NOS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="420"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only participants registered after 07-12-2007 were able to participate in the quality of life / patient reported outcome study components.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Wendy Seiferheld</name_or_title>
      <organization>Radiation Therapy Oncology Group (RTOG)</organization>
      <email>wseiferheld@acr.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

